Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 707

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 707
---
26 years of
experience in the pharmaceutical industry. During his pharmaceutical career, he has had both broad-based drug and device development
expertise in a variety of therapeutic areas. Dr. Lang has experience in designing development programs from early translational
stages through phase III including the successful filing of several recent INDs and NDAs. He has experience with regulatory interactions
and negotiations with FDA and various European and Asian Authorities. Dr. Lang received his Doctor of Medicine from Ben-Gurion
University of the Negev and completed post graduate training at Emory University in Atlanta, GA. 

Todd
Davis has served as a member of our board of directors since January 2023. He is the Chief Executive Officer of Ligand
Pharmaceuticals Incorporated since December 2022 and is a member of the board of directors since 2007. He is the founder and has
served as the managing partner of RoyaltyRx Capital, LLC, a special opportunities investment firm, since 2018. Since November
2019, he has also served as Chairman and CEO of Benuvia Holdings, LLC, a pharmaceutical holding company. From 2006 to 2018, Mr.
Davis was a founder and Managing Partner of HealthCare Royalty Partners, a global healthcare investment firm. From 2004 to 2006,
Mr. Davis was a partner at Paul Capital Partners, where he co-managed its royalty investments as a member of the Royalty Management
Committee. From 2001 to 2004, he served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners.
Mr. Davis began his business career in sales at Abbott Laboratories where he held several commercial roles of increasing responsibility.
He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a navy
veteran and received a B.S. from the U.S. Naval Academy and an M.B.A. from the Harvard Business School. He currently serves on
the board of directors of Palvella Therapeutics Inc., Virocell Biologics and Ligand Pharmaceuticals Incorporated. He is also a
former board member of the Harvard Business School Healthcare Alumni Association. We believe Mr. Davis is qualified to serve on
the board of directors because of his extensive experience within the life sciences industry, including as a founder and managing
partner of a special opportunities investment firm.

Ezra
Friedberg has served on our board of directors since May 2021